Vor Bio to Participate in Upcoming Investor Conferences
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
马萨诸塞州剑桥,2024年4月1日(GLOBE NEWSWIRE)——临床阶段的细胞和基因组工程公司Vor Bio(纳斯达克股票代码:VOR)今天宣布将参加以下即将举行的投资者会议:
23rd Annual Needham Virtual Healthcare Conference
Fireside Chat: Tuesday, April 9, 2024 at 3:45 pm ET
Location: Virtual
第 23 届年度 Needham 虚拟医疗会议
炉边谈话:美国东部时间 2024 年 4 月 9 日星期二下午 3:45
地点:虚拟
Chardan's 8th Annual Genetic Medicines + Cell Therapy Manufacturing Summit
Fireside Chat: Monday, April 29, 2024 at 9:30 am ET
Location: Virtual
Chardan的第八届年度遗传药物+细胞疗法制造峰会
炉边谈话:美国东部时间 2024 年 4 月 29 日星期一上午 9:30
地点:虚拟
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
关于 Vor Bio
Vor Bio是一家处于临床阶段的细胞和基因组工程公司,旨在通过设计造血干细胞来实现移植后的靶向治疗,从而改变血液癌患者的护理标准。欲了解更多信息,请访问: www.vorbio.co。
Contact:
联系人:
Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
媒体与投资者
莎拉·斯宾塞
+1 857-242-6076
sspencer@vorbio.com